Denali Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Denali Therapeutics (NASDAQ:DNLI) reported Q4 earnings with an EPS of $-0.86, missing estimates by -7%, and a revenue decrease of $10.28M from the previous year. This follows a pattern of mixed past earnings performances, including a notable beat in Q2 2023 but a subsequent 5% share price drop.
February 27, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Denali Therapeutics reported a Q4 EPS of $-0.86, missing estimates by -7%, and a decrease in revenue, indicating potential short-term negative impact on its stock price.
The missed earnings estimate and revenue decrease are typically seen as negative indicators by investors, potentially leading to a short-term decrease in stock price. This is supported by past performance where a beat in EPS was followed by a 5% drop in share price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100